Mike Dunn, M.B.A., is the President and Chief Operating Officer at Calcimedica (NASDAQ: CALC). Prior to joining Calcimedica Mr. Dunn held senior management positions as Senior VP Corporate Development at Biocept, Inc., as well as VP and Chief Business Officer at Monogram Biosciences and ACLARA Biosciences, and VP of Business Development at Aurora Biosciences, each of which merged or were acquired. He also served as the VP of Business Development at the Salk Institute Biotechnology and Industrial Associates Inc. (SIBIA). Mr. Dunn obtained his MBA in Finance at the University of San Diego and BA in Biology at the University of Chicago.
Dr. Guzman, is the Vice Chair of the Board of Rakuten Medical, a privately held company that he founded (formerly Aspyrian Therapeutics) to develop an innovative photoimmunotherapy platform for the treatment of solid tumor cancers, which has raised over $618M through 9 rounds of funding. Dr. Guzman previously served as the CSO, President and CEO at Rakuten Medical. Prior to founding Aspyrian / Rakuten Medical he previously held positions as Associate Director and Research Fellow at Vertex Pharmaceuticals. Before joining industry, Dr. Guzman held academic postdoctoral research positions at the Sanford Burnham Institute in San Diego and the Max Planck Institute for Experimental Medicine in Göttingen, Germany after obtaining his PhD in Neuroscience at the University of Alicante Institute of Neurosciences and a BS in Chemistry the University of Alicante, in Valencia Spain.
Dr. Henkel, Co-Founder, Senior Vice President and Chief Product Development Officer of Arisan Therapeutics, manages advanced preclinical and drug product development operations while also supporting clinical development efforts. Previously, Dr. Henkel led drug development programs at Vertex Pharmaceuticals including his role as Director of Biology, after completing a postdoctoral fellowship at the Burnham Institute. He obtained his PhD in Immunology at the Oregon Health & Science University and a BS in Biochemistry at the California Polytechnic State University, San Luis Obispo CA.
Dr. McCormack, Founder of Arisan Therapeutics, serves as President and Chief Scientific Officer, managing drug discovery, clinical and corporate operations, and held previous scientific and management positions at Narogen, Icagen and Vertex Pharmaceuticals. Dr. McCormack completed postdoctoral fellowships at the University of Wisconsin, the Max Planck Institute for Experimental Medicine and Max Planck Institute for Biophysical Chemistry in Göttingen, Germany, as well as the Yale University School of Medicine. He obtained his PhD in Biology at the California Institute of Technology.
Dr. McCormack, who previously held scientific and management positions at Narogen, Icagen and Vertex Pharmaceuticals, manages the drug discovery and clinical programs and corporate operations.
Dr. Henkel manages preclinical and drug product development operations while supporting clinical development efforts. Dr. Henkel led Arisan’s Investigational New Drug (IND) Application efforts for ARN-75039 to enable clinical phase funding and study efforts.
Ms. Howard manages contract accounting and financial operations.
Mr. Neidert provides strategic IP management and maintenance of Arisan’s US and international patent portfolio. Mr Neidert obtained his JD in Law at the Cleveland State University Marshall College of Law and obtained his BS in Chemistry at Washington University in St Louis Missouri.
Mr. Heredia and the California Counsel Group provide general and corporate counsel for Arisan. Mr. Heredia obtained a JD in law and an M.B.A from Stanford University after obtaining a BA in Economics-Business from the University of California at Los Angeles.
Mr. Murphy is responsible for database and IT systems management.
Arisan’s scientific efforts are conducted by a team of dedicated biologists, virologists and medicinal and analytical chemists with extensive drug discovery and development experience, whose efforts are supported by a host of highly experienced consultants and collaborators, all made possible through funding from DTRA, Battelle and the National Institute for Allergy and Infectious Disease.